Table 1. Recent clinical trials of CRS/HIPEC

Trials	Enrollment period	Country	Published	Control vs. experimental arm	HIPEC (drug, dose)	Inclusion criteria
Netherland trial [2]	1998−2001	Netherlands	2003	Systemic CTx (n=51) vs. CRS/HIPEC+adjuvant CTx (n=54)	Mitomycin-C 35 mg/m2	CRC PM
PRODIGE-7 [41]	2008−2014	France	2021	CRS (n=132) vs. CRS/HIPEC (n=133) followed by adjuvant CTx	Oxaliplatin 360−460 mg/m2 +IV 5-FU/LV	CRC PM, PCI<26
ProphyloCHIP [46]	2010−2015	France	2020	Surveillance vs. Second-look surgery+HIPEC	Oxaliplatin 360−460 mg/m2 +IV 5-FU/LV or Mitomycin-C 35 mg/m2	Patients with resected synchronized localized CRC PM or perforated tumor
COLOPEC [47]	2015−2017	Netherlands	2019	Adjuvant CTx vs. Adjuvant HIPEC+adjuvant CTx	Oxaliplatin 360−460 mg/m2 +IV 5-FU/LV	Resected T4N0-2M0 or perforated CRC
HIPECT4 [48]	2018−2021	Spain	2023	Adjuvant CTx vs. Adjuvant CTx+HIPEC	Mitomycin-C 30 mg/m2, 60 min	Resected cT4NxMx CRC

CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; CTx, chemotherapy; CRC, colorectal cancer; PM, peritoneal metastasis; PCI, peritoneal cancer index.